SKORVANEK, M., J.G. GOLDMAN, M. JAHANSHAHI, C. MARRAS, Irena REKTOROVÁ, B. SCHMAND, E. VAN DUIJN, C.G. GOETZ, D. WEINTRAUB, G.T. STEBBINS and P. MARTINEZ-MARTIN. Reply: MoCA for Cognitive Screening in Parkinson's Disease: Beware of Floor Effect. Movement Disorders. Hoboken: Wiley-Blackwell, 2018, vol. 33, No 3, p. 499-500. ISSN 0885-3185. Available from: https://dx.doi.org/10.1002/mds.27339.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Reply: MoCA for Cognitive Screening in Parkinson's Disease: Beware of Floor Effect
Authors SKORVANEK, M. (703 Slovakia), J.G. GOLDMAN (840 United States of America), M. JAHANSHAHI (826 United Kingdom of Great Britain and Northern Ireland), C. MARRAS (124 Canada), Irena REKTOROVÁ (203 Czech Republic, guarantor, belonging to the institution), B. SCHMAND (528 Netherlands), E. VAN DUIJN (528 Netherlands), C.G. GOETZ (840 United States of America), D. WEINTRAUB (840 United States of America), G.T. STEBBINS (840 United States of America) and P. MARTINEZ-MARTIN (724 Spain).
Edition Movement Disorders, Hoboken, Wiley-Blackwell, 2018, 0885-3185.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 8.222
RIV identification code RIV/00216224:14740/18:00106659
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1002/mds.27339
UT WoS 000426736900028
Keywords in English Mild Cognitive Impairment; Dementia; cognitive screening
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 19/3/2019 15:11.
Abstract
Federico et al1 discuss the differences in normative values for global cognitive scales, including the Montreal Cognitive Assessment (MoCA) and the MiniMental State Examination (MMSE), across different populations, as well as sensitivity of these scales for detection of Parkinson's disease related mild cognitive impairment (PDMCI) at level I (Movement Disorder Society PDMCI Task Force diagnostic criteria). The issue of normative values is an important one, and caution should be exercised when interpreting results of cognitive testing in different patient populations. As discussed in our article,2 factors such as age, language, and education level often can affect results of cognitive testing. Moreover, the selection of the normative comparison group for cognitive testing plays an important role in interpreting cognitive testing results as well, and differences in “control” populations can lead to significantly differing normative values. Although some studies exclude participants as “healthy control” subjects only if they endorse subjective cognitive complaints, others apply more detailed and stricter criteria in which participants would be excluded as “healthy controls”: if they have other factors as well, for example, subjective complaints of memory loss, systemic illness, drug or alcohol use, or any abnormality on in depth neuropsychological assessment, neurologic examination, and brain imaging studies.3 These differences in definitions of “healthy control” populations thereby may lead to under or overestimation of PD MCI in the PD population.
PrintDisplayed: 22/7/2024 12:25